PROsPeR评分在低反应患者中预测活产结局的观察性验证
本研究基于法国8个中心的8085个ART治疗周期,外部验证PROsPeR评分在ESHRE Bologna标准定义的POR患者中区分活产结局的能力,并与ESPART RCT数据(477周期)比较。结果显示观察队列AUC为0.688(95%CI 0.662-0.714),ESPART队列AUC为0.695(95%CI 0.623-0.767),AUC差异-0.0074(95%CI -0.083-0.0689),校正良好(Hosmer-Lemeshow P=0.260)。
要点
- PROsPeR评分可区分POR患者活产概率,AUC约70%。
- 观察队列与RCT队列AUC差异小,精度损失低于预设10%界值。
- 评分基于年龄、AMH和既往取卵数三项易得指标。
核心结论
- PROsPeR评分在观察性数据中能区分POR患者活产结局,区分度一般(AUC≅70%)且校正良好。
- 与基于RCT数据开发的模型相比,AUC精度损失小于5%。
研究设计与样本
- 外部验证研究,使用法国8个中心的观察性数据。
- 观察队列纳入8085个使用follitropin alfa治疗的POR患者ART周期。
- 参考队列为ESPART RCT中477个使用follitropin alfa的POR患者ART周期。
主要发现
- 观察队列AUC=0.688(95%CI: 0.662, 0.714),ESPART队列AUC=0.695(95%CI: 0.623, 0.767)。
- AUC差异为-0.0074(95%CI: -0.083, 0.0689),最大估计损失8.4%,低于预设10%界值。
- Hosmer-Lemeshow检验=1.266688,P=0.260,未拒绝校正。
关键数值与推荐
- POR定义采用ESHRE Bologna标准(女性年龄、AMH、既往周期取卵数)。
- PROsPeR评分将POR分为轻度、中度、重度,基于女性年龄、血清AMH和既往取卵数。
- 非劣效界值为AUC差异0.10。
临床怎么用
- 可利用女性年龄、血清AMH和既往取卵数三项指标计算POR患者活产概率。
- 评分可用于比较同一中心随时间或不同中心间的绩效。
局限性
- 基于二次利用数据,非专门为本次分析收集。
- 分类特征限于可用数据,数据来自单一国家有限中心,可能存在偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can the Poor Responder Outcome Prediction (PROsPeR) score identify live birth outcomes in subpopulations of patients with poor ovarian response (POR) defined according to the ESHRE Bologna criteria (female age, anti-Müllerian hormone (AMH), number of oocytes retrieved during the previous cycle (PNO) after treatment with originator recombinant human follitropin alfa? SUMMARY ANSWER: The PROsPeR score discriminated the probability of live birth in patients with POR using observational data with fair discrimination (AUC ≅ 70%) and calibration, and the AUC losing less than 5% precision compared with a model developed using the observational data. WHAT IS KNOWN ALREADY: Although scoring systems for the likelihood of live birth after ART have been developed, their accuracy may be insufficient, as they have generally been developed in the general population with infertility and were not validated for patients with POR. The PROsPeR score was developed using data from the follitropin alfa (GONAL-f; Merck KGaA, Darmstadt, Germany) arm of the Efficacy and Safety of Pergoveris in Assisted Reproductive Technology (ESPART) randomized controlled trial (RCT) and classifies women with POR as mild, moderate or severe, based upon three variables: female age, serum AMH level and number of oocytes retrieved during the previous cycle (PNO). STUDY DESIGN, SIZE, DURATION: The external validation of the PROsPeR score was completed using data derived from eight different centres in France. In addition, the follitropin alfa data from the ESPART RCT, originally used to develop the PROsPeR score, were used as reference cohort. The external validation of the PROsPeR score l was assessed using AUC. A predetermined non-inferiority limit of 0.10 compared with a reference sample and calibration (Hosmer-Lemeshow test) were the two conditions required for evaluation. PARTICIPANTS/MATERIALS, SETTING, METHODS: The observational cohort included data from 8085 ART treatment cycles performed with follitropin alfa in patients with POR defined according to the ESHRE Bologna criteria (17.6% of the initial data set). The ESPART cohort included 477 ART treatment cycles with ovarian stimulation performed with follitropin alfa in patients with POR. MAIN RESULTS AND THE ROLE OF CHANCE: The external validation of the PROsPeR score to identify subpopulations of women with POR with different live birth outcomes was shown in the observational cohort (AUC = 0.688; 95% CI: 0.662, 0.714) compared with the ESPART cohort (AUC = 0.695; 95% CI: 0.623, 0.767). The AUC difference was -0.0074 (95% CI: -0.083, 0.0689). This provided evidence, with 97.5% one-sided confidence, that there was a maximum estimated loss of 8.4% in discrimination between the observational cohort and the ESPART cohort, which was below the predetermined margin of 10%. The Hosmer-Lemeshow test did not reject the calibration when comparing observed and predicted data (Hosmer-Lemeshow test = 1.266688; P = 0.260). LIMITATIONS, REASONS FOR CAUTION: The study was based on secondary use of data that had not been collected specifically for the analysis reported here and the number of characteristics used to classify women with POR was limited to the available data. The data were from a limited number of ART centres in a single country, which may present a bias risk; however, baseline patient data were similar to other POR studies. WIDER IMPLICATIONS OF THE FINDINGS: This evaluation of the PROsPeR score using observational data supports the notion that the likelihood of live birth may be calculated with reasonable precision using three readily available pieces of data (female age, serum AMH and PNO). The PROsPeR score has potential to be used to discriminate expected probability of live birth according to the degree of POR (mild, moderate, severe) after treatment with follitropin alfa, enabling comparison of performance at one centre over time and the comparison between centres. STUDY FUNDING/COMPETING INTEREST(S): This analysis was funded by Merck KGaA, Darmstadt, Germany. P.L. received grants from Merck KGaA, outside of the submitted work. N.M. reports grants, personal fees and non-financial support from Merck KGaA outside the submitted work. T.D.H. is Vice President and Head of Global Medical Affairs Fertility, Research and Development at Merck KGaA, Darmstadt, Germany. P.A. has received personal fees from Merck KGaA, Darmstadt, Germany, outside the submitted work. C.R. has received grants and personal fees from Gedeon Richter and Merck Serono S.A.S., France, an affiliate of Merck KGaA, Darmstadt, Germany, outside the submitted work. P.S. reports congress support from Merck Serono S.A.S., France (an affiliate of Merck KGaA, Darmstadt, Germany), Gedeon Richter, TEVA and MDS outside the submitted work. C.A., J.P., G.P. and R.W. declare no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Lehert P, Arvis P, Avril C, et al. A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome. Hum Reprod. 2021. PMID: 33860313. doi:10.1093/humrep/deab050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。